RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Real-time Estimate Cboe Europe  -  05/18 08:13:47 am EDT
0.0580 CHF    0.00%
05/11Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQ
05/09Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
AQ
05/09Relief Therapeutics to Participate in Industry and Investor Conferences in May
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

US FDA Denies Breakthrough Therapy Designation For Relief Therapeutics' COVID-19 Drug

11/24/2021 | 01:26am EDT


© MT Newswires 2021
All news about RELIEF THERAPEUTICS HOLDING AG
05/11Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F wi..
EQ
05/09Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the..
AQ
05/09Relief Therapeutics to Participate in Industry and Investor Conferences in May
EQ
05/06Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the..
AQ
05/06Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the..
EQ
05/06Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer..
CI
05/06Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS H..
EQ
04/27Relief Therapeutics Unit Secures Notice Of Allowance For Patent Claims Covering Amino A..
MT
04/27Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Not..
EQ
04/26Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marke..
EQ
More news
Financials
Sales 2022 20,0 M 20,1 M 20,1 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 239 M 241 M 241 M
Capi. / Sales 2022 11,9x
Capi. / Sales 2023 2,49x
Nbr of Employees 10
Free-Float 66,6%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,06 CHF
Average target price 0,41 CHF
Spread / Average Target 598%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Taneli Jouhikainen Chief Operating Officer
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-6.75%241
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002